Analysis of M2 macrophage-associated risk score signature in pancreatic cancer TME landscape and immunotherapy

Background: M2 macrophages perform an influential role in the progression of pancreatic cancer. This study is dedicated to explore the value of M2 macrophage-related genes in the treatment and prognosis of pancreatic cancer. Methods: RNA-Seq and clinical information were downloaded from TCGA, GEO and ICGC databases. The pancreatic cancer tumour microenvironment was revealed using the CIBERSORT algorithm. Weighted gene co-expression network analysis (WGCNA) was used to detect M2 macrophage-associated gene modules. Univariate Cox regression, Least absolute shrinkage and selection operator (LASSO) regression analysis and multivariate Cox regression were applied to develop the prognostic model. The modelling and validation cohorts were divided into high-risk and low-risk groups according to the median risk score. The nomogram predicting survival was constructed based on risk scores. Correlations between risk scores and tumour mutational load, clinical variables, immune checkpoint blockade, and immune cells were further explored. Finally, potential associations between different risk models and chemotherapeutic agent efficacy were predicted. Results: The intersection of the WGCNA results from the TCGA and GEO data screened for 317 M2 macrophage-associated genes. Nine genes were identified by multivariate COX regression analysis and applied to the construction of risk models. The results of GSEA analysis revealed that most of these genes were related to signaling, cytokine receptor interaction and immunodeficiency pathways. The high and low risk groups were closely associated with tumour mutational burden, immune checkpoint blockade related genes, and immune cells. The maximum inhibitory concentrations of metformin, paclitaxel, and rufatinib lapatinib were significantly differences on the two risk groups. Conclusion: WGCNA-based analysis of M2 macrophage-associated genes can help predict the prognosis of pancreatic cancer patients and may provide new options for immunotherapy of pancreatic cancer.

[1]  Axel Behrens,et al.  The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma , 2022, Oncogene.

[2]  J. Kleeff,et al.  Analysis of genomic alterations in cancer associated human pancreatic stellate cells , 2022, Scientific Reports.

[3]  P. Burchard,et al.  Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yusheng Chen,et al.  Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma , 2022, Oncogenesis.

[5]  M. Pittet,et al.  Clinical relevance of tumour-associated macrophages , 2022, Nature Reviews Clinical Oncology.

[6]  R. Chammas,et al.  Phosphatidylcholine-Derived Lipid Mediators: The Crosstalk Between Cancer Cells and Immune Cells , 2022, Frontiers in Immunology.

[7]  Youwei Zhu,et al.  The CTCF/LncRNA‐PACERR complex recruits E1A binding protein p300 to induce pro‐tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating PTGS2 expression , 2022, Clinical and translational medicine.

[8]  V. J. Sánchez-Arévalo Lobo,et al.  Tumour microenvironment and heterotypic interactions in pancreatic cancer , 2022, Journal of Physiology and Biochemistry.

[9]  James M. McFarland,et al.  Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer , 2021, Cell.

[10]  A. Perrakis,et al.  Structure and function of the ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) family: Tidying up diversity , 2021, The Journal of biological chemistry.

[11]  M. Racchi,et al.  Molecular Characterization of Membrane Steroid Receptors in Hormone-Sensitive Cancers , 2021, Cells.

[12]  V. Setiawan,et al.  Changes in metabolic syndrome and its implications on the risk and racial/ethnic disparities of pancreatic cancer. , 2021, Gastroenterology.

[13]  J. Feliu,et al.  Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer , 2021, World journal of gastroenterology.

[14]  G. Duda,et al.  The multifaceted roles of macrophages in bone regeneration: A story of polarization, activation and time. , 2021, Acta biomaterialia.

[15]  H. Zhan,et al.  Macrophages in pancreatic cancer: An immunometabolic perspective. , 2020, Cancer letters.

[16]  Xianjun Yu,et al.  Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma , 2020, Journal of Hematology & Oncology.

[17]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[18]  E. Jaffee,et al.  Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. , 2020, The Lancet. Oncology.

[19]  T. Schumacher,et al.  Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells , 2020, bioRxiv.

[20]  Jianxun Song,et al.  Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma , 2020, Molecular Cancer.

[21]  A. Mantovani,et al.  Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.

[22]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[23]  S. Gordon,et al.  The Mononuclear Phagocytic System. Generation of Diversity , 2019, Front. Immunol..

[24]  L. Shevde,et al.  The Tumor Microenvironment Innately Modulates Cancer Progression. , 2019, Cancer research.

[25]  E. Karamitopoulou.  Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features , 2019, British Journal of Cancer.

[26]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[27]  C. Glass,et al.  Analysis of Genetically Diverse Macrophages Reveals Local and Domain-wide Mechanisms that Control Transcription Factor Binding and Function , 2018, Cell.

[28]  A. Maitra,et al.  Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling. , 2018, Cancer discovery.

[29]  S. Pushalkar,et al.  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. , 2018, Cancer discovery.

[30]  J. Kzhyshkowska,et al.  Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy. , 2017, Current pharmaceutical design.

[31]  S. Snapper,et al.  Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages , 2017, Science.

[32]  F. Real,et al.  Choline Kinase Alpha (CHKα) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors , 2016, Molecular Cancer Therapeutics.

[33]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[34]  E. Raymond,et al.  Targeting cancer cell metabolism in pancreatic adenocarcinoma , 2015, Oncotarget.

[35]  P. Taylor,et al.  Tissue-resident macrophages: then and now , 2015, Immunology.

[36]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[37]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[38]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[39]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[40]  H. Taboada.  [The mononuclear phagocytic system]. , 1976, Revista chilena de pediatria.

[41]  Mingye Feng,et al.  Targeting tumor-associated macrophages for cancer immunotherapy. , 2022, International review of cell and molecular biology.

[42]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[43]  Manuel Hidalgo,et al.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes. , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[44]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .